CLASS II ONGOING Device recall · Reported 30 Aug 2023 · FDA Enforcement Report

Randox Liquid Urine Control Level 2- intended recalled

Randox Laboratories is recalling Randox Liquid Urine Control Level 2- intended for in vitro diagnostic use, in the quality, distributed nationwide in the US. The recall was initiated on 21 Jun 2023 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesGTIN: 05055273207569 Batch/Lot Number: 1209UC Expiry Date: 28 Mar 24
Quantity recalled39 units

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-2446-2023
FDA event ID
92710
Recalling firm
Randox Laboratories, Crumlin (North), N/A
Classification
Class II
Status
Ongoing
Recall initiated
21 Jun 2023
FDA classified
23 Aug 2023
Reported
30 Aug 2023
Type
Voluntary: Firm initiated
Customers notified by
E-Mail
Reason category
Device Malfunction

Timeline

21 Jun 2023Recall initiated by company
23 Aug 2023Classified by FDA+63 days
30 Aug 2023Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

(1) There is vial to vial variation resulting in some vials recovering positive for hCG, which should be negative and (2) high and outside range for cortisol. (3) There has been a transcription error for Creatinine in the Instructions For Use (IFU). The target and ranges for Creatinine for the Roche Creatinine Plus method have been listed incorrectly. These failures cause a delay in patient results for the above mentioned analytes.

Device recalls are issued when a component, software or design fault could cause the device to fail or give wrong readings. Many are corrections applied in the field rather than physical returns.

Product as listed by the FDA

Randox Liquid Urine Control Level 2- intended for in vitro diagnostic use, in the quality control of Amylase, Calcium, Chloride, Cortisol, Creatinine, Glucose, hCG pregnancy, Magnesium, Microalbumin, Osmolality, pH, Phosphate Inorganic, Potassium, Protein Total, Sodium, Specific Gravity, Urea and Uric Acid (Urate) on clinical chemistry systems Catalog Number: UC5074

Where it was distributed

Worldwide distribution - US Nationwide distribution in the states of AR, FL, GA, OH, VA including PR and WW distribution.

Nationwide ArkansasFloridaGeorgiaOhioPuerto RicoVirginia

Questions about this recall

Why was it recalled?

(1) There is vial to vial variation resulting in some vials recovering positive for hCG, which should be negative and (2) high and outside range for cortisol. (3) There has been a transcription error for Creatinine in the Instructions For Use (IFU). The target and ranges for Creatinine for the Roche Creatinine Plus method have been listed incorrectly. These failures cause a delay in patient results for the above mentioned analytes.

Which lots are affected?

GTIN: 05055273207569 Batch/Lot Number: 1209UC Expiry Date: 28 Mar 24

Where was it sold?

Worldwide distribution - US Nationwide distribution in the states of AR, FL, GA, OH, VA including PR and WW distribution.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Randox Laboratories

All 98

Other Insulin Pumps & Glucose Monitors recalls

All 465